Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 10:15:100186.
doi: 10.1016/j.obpill.2025.100186. eCollection 2025 Sep.

Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study

Affiliations

Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study

W Scott Butsch et al. Obes Pillars. .

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) drug-induced weight loss is associated with fat mass reduction but can also lead to nutritional deficiencies and loss of muscle. We quantified nutritional deficiencies in adults who had undergone GLP-1RA treatment.

Methods: This was an observational, retrospective analysis of de-identified patient-level claims data from 461,382 adults newly prescribed GLP-1RAs between 7/2017 and 12/2021 with no prior diagnoses of nutritional deficiencies. While most patients had type 2 diabetes (T2DM), the population also included individuals with type 1 diabetes (T1DM), prediabetes, or no recorded diabetes diagnosis. A secondary propensity-matched analysis compared GLP-1RA users with non-users. The matched comparator cohort consisted of adults with type 2 diabetes treated with metformin but not prescribed GLP-1RAs, whereas GLP-1RA users were treated with both metformin and GLP-1RA. Nutritional deficiencies were assessed at 6 and 12 months after GLP-1RA initiation. Nutritional deficiency diagnoses or complications were compared between patients with or without a dietitian visit within a 6-months of treatment initiation.

Results: Patients were mainly female (56.3 %), mean age (±SD) 52.9 (±11.7) years, with obesity (44.9 %) or overweight (5.6 %); type 2 diabetes (80.5 %) and hypertension (66.3 %) were the most common comorbidities. Nutritional deficiencies were diagnosed in 12.7 % of the patients within 6 months after GLP-1RA initiation and in 22.4 % within 12 months. Vitamin D deficiency was most common, having an incidence of 7.5 % and 13.6 % within 6 and 12 months, respectively. Recorded nutrient deficiencies or deficiency-related complications were more likely among patients with a dietitian visit within the first 6 months of GLP-1RA initiation compared to patients without a dietitian visit.

Conclusion: Over 20 % had nutritional deficiencies diagnosed within one-year of starting GLP-1RA treatment. These findings highlight the importance of nutritional screening and diagnosis of deficiencies and inclusion of physician nutrition specialists, dietitians, and other nutrition care specialists in patient care.

Keywords: Dietitian; Glucagon-like peptide-1 receptor agonists; Nutritional deficiency; Obesity; Overweight; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

S Sulo, AT Chang, JA Kim, KW Kerr, DR Williams, R Hegazi, T Panchalingam, and S Goates are employees of Abbott. S Butsch and S Heymsfield performed work on this study under contract with Abbott.

Figures

Image 1
Graphical abstract

References

    1. Centers for Disease Control and Prevention . 2023. National diabetes statistics report website.
    1. IDF Diabetes Atlas International Diabetes Federation . tenth ed. IDF; Brussels, Belgium: 2021. IDF diabetes atlas.
    1. Hruby A., Hu F.B. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–689. - PMC - PubMed
    1. World Obesity Federation . 2023. World obesity atlas.
    1. Donini L.M., Busetto L., Bischoff S.C., Cederholm T., Ballesteros-Pomar M.D., Batsis J.A., et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr (Edinb) 2022;41:990–1000. - PubMed

LinkOut - more resources